Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

21. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study 29888547 2018 07 10 1463-1326 2018 Jun 11 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. 10.1111/dom.13413 Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2 (...) ). This study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with type 2 diabetes (T2D) and moderate renal impairment (estimated glomerular filtration rate [eGFR], 45-59 mL/min/1.73 m 2 ; chronic kidney disease [CKD] stage 3A). In this double-blind, parallel group, Phase 3 study (NCT02413398, clinicaltrials.gov) patients with inadequately controlled T2D (HbA1c 7.0%-11.0%) were randomized (1:1) to dapagliflozin 10 mg once daily (N = 160) or matching placebo (N = 161) for 24

EvidenceUpdates2018

22. Chronic Kidney Disease, Queensland (CKD.QLD) Registry: Management of CKD With Telenephrology

Chronic Kidney Disease, Queensland (CKD.QLD) Registry: Management of CKD With Telenephrology 30450460 2018 12 07 2468-0249 3 6 2018 Nov Kidney international reports Kidney Int Rep Chronic Kidney Disease, Queensland (CKD.QLD) Registry: Management of CKD With Telenephrology. 1336-1343 10.1016/j.ekir.2018.07.013 Enabled by the Chronic Kidney Disease, Queensland (CKD.QLD) Registry, we aim to outline the structure, implementation, and outcomes of telenephrology clinics for the management of patients (...) with chronic kidney disease (CKD) in rural, regional, and remote areas of the Darling Downs region in Queensland, Australia. This is an observational registry-based study involving adult patients with CKD, attending specialist clinics, and residing ≥50 km away from Toowoomba Hospital. The telenephrology cohort (TC) included those who had their follow-up appointments via videoconference at local Queensland Health facilities, and the standard care cohort (SCC) included those who continue to have their follow

Kidney international reports2018 Full Text: Link to full Text with Trip Pro

23. Metabolic syndrome and its components are associated with increased chronic kidney disease risk: Evidence from a meta-analysis on 11 109 003 participants from 66 studies

Metabolic syndrome and its components are associated with increased chronic kidney disease risk: Evidence from a meta-analysis on 11 109 003 participants from 66 studies 29790628 2018 05 23 1742-1241 2018 May 23 International journal of clinical practice Int. J. Clin. Pract. Metabolic syndrome and its components are associated with increased chronic kidney disease risk: Evidence from a meta-analysis on 11 109 003 participants from 66 studies. e13201 10.1111/ijcp.13201 Observational studies (...) examining the relationship between metabolic syndrome and the risk of chronic kidney disease (CKD) have reported inconclusive results. This meta-analysis was performed to resolve these controversies. The MEDLINE, EMBASE, and PubMed databases were systematically searched from their inception until March 2016 to identify all relevant studies. Risk estimates and their corresponding 95% confidence intervals (CIs) for the associations of MetS and its components with CKD risk were extracted and pooled using

EvidenceUpdates2018

24. Chronic kidney disease

Chronic kidney disease Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) to (we will only get better by constructive feedback). For a list of known issues . Also read , explaining issues with the system. To get started, type a condition/disease into the search box above. Here are some examples to get you started: Performing Autosynthesis X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2017 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

Trip Evidence Maps2018

25. Inhibition of Interleukin-1beta by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

Inhibition of Interleukin-1beta by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease 29793629 2018 05 25 1558-3597 71 21 2018 May 29 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. 2405-2414 S0735-1097(18)34271-2 10.1016/j.jacc.2018.03.490 Inflammation contributes to chronic kidney disease (CKD), in part mediated through activation (...) of interleukin (IL)-1β by the NLRP3 inflammasome within the kidney. This process also likely contributes to the accelerated atherosclerosis associated with nephropathy. The authors hypothesized that canakinumab, a human monoclonal antibody targeting IL-1β, might reduce cardiovascular event rates and improve renal function among post-myocardial infarction patients with CKD. Stable post-myocardial infarction patients with high-sensitivity C-reactive protein (hsCRP) ≥ 2mg/l were randomly allocated to placebo

EvidenceUpdates2018

26. Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial.

Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial. Importance: In observational studies, increased water intake is associated with better kidney function. Objective: To determine the effect of coaching to increase water intake on kidney function in adults with chronic kidney disease. Design, Setting, and Participants: The CKD WIT (Chronic Kidney Disease Water Intake Trial) randomized clinical trial (...) was conducted in 9 centers in Ontario, Canada, from 2013 until 2017 (last day of follow-up, May 25, 2017). Patients had stage 3 chronic kidney disease (estimated glomerular filtration rate [eGFR] 30-60 mL/min/1.73 m2 and microalbuminuria or macroalbuminuria) and a 24-hour urine volume of less than 3.0 L. Interventions: Patients in the hydration group (n = 316) were coached to drink more water, and those in the control group (n = 315) were coached to maintain usual intake. Main Outcomes and Measures

JAMA2018

27. Gout medication may slow progression of chronic kidney disease

Gout medication may slow progression of chronic kidney disease NIHR DC | Signal - Gout medication may slow progression of chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover Gout medication may slow progression of chronic kidney disease Published on 20 February 2018 In people with existing kidney disease, one in four will have worse disease within six to 12 months. Uric acid-lowering drugs such as allopurinol halve the risk of disease progression over this period (...) . They also reduce heart attack or stroke by 60%. Uric acid, the cause of gout, is produced when proteins are broken down by the body. It is excreted by the kidneys and often builds up in people with chronic kidney disease. It is not certain whether increased uric acid causes progression of kidney disease or is simply a marker of its severity. This review included 16 small trials of 1,211 people with moderate chronic kidney disease from a variety of causes which were allocated to take a uric acid lowering

NIHR Dissemination Centre2018

28. Uncertainty persists over choice of phosphate binders for chronic kidney disease

Uncertainty persists over choice of phosphate binders for chronic kidney disease NIHR DC | Signal - Uncertainty persists over choice of phosphate binders for chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Uncertainty persists over choice of phosphate binders for chronic kidney disease Published on 30 August 2016 NICE recommend calcium-based phosphate binding medicines for people with chronic kidney disease, however, new research suggests non-calcium (...) based alternatives might lead to a lower risk of death. The review is best viewed alongside other reviews which look at different aspects of chronic kidney disease. The totality of research and cost effectiveness will need to be considered if practice recommendations are to change. In this review, calcium-based phosphate binders were associated with increased risk of death compared with non-calcium alternatives, but there was no difference in the risk of cardiovascular death or hospitalisation

NIHR Dissemination Centre2018

29. New generation anticoagulants may be safer than warfarin for people with chronic kidney disease

New generation anticoagulants may be safer than warfarin for people with chronic kidney disease NIHR DC | Signal - New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Published on 26 April 2016 Newer generation anticoagulants appear to reduce the risk of bleeding compared with older (...) anticoagulants like warfarin, when used to prevent clots in people who also have mild to moderate chronic kidney disease. This group of drugs, called direct oral anticoagulants, have been well researched in healthy people with atrial fibrillation or at risk of thromboembolism but this was the first review to look at their safety, in terms of bleeding and risk of bleeding within the brain, in people with kidney disease. As a group, these newer drugs appear safer than older anticoagulants such as warfarin

NIHR Dissemination Centre2018

30. Chronic kidney disease care models in low- and middle-income countries: a systematic review

Chronic kidney disease care models in low- and middle-income countries: a systematic review 29629191 2018 11 14 2059-7908 3 2 2018 BMJ global health BMJ Glob Health Chronic kidney disease care models in low- and middle-income countries: a systematic review. e000728 10.1136/bmjgh-2018-000728 The number of persons with chronic kidney disease (CKD) living in low- and middle-income countries (LMIC) is increasing rapidly; yet systems built to care for them have received little attention. In order (...) and identified 17 articles describing 16 programmes from 10 countries for inclusion. National efforts (n=4) focused on the prevention of end-stage renal disease through enhanced screening, public awareness campaigns and education for primary care providers. Of the 12 clinical care models, nine focused on persons with CKD and the remaining on persons at risk for CKD; a majority in the first category implemented a multidisciplinary clinic with allied health professionals or primary care providers (rather than

BMJ global health2018 Full Text: Link to full Text with Trip Pro

31. Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018

Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018 29607300 2018 11 14 2450-131X 6 1 2018 03 Journal of translational internal medicine J Transl Int Med Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018. 21-25 10.2478/jtim-2018-0005 Statins essentially are cholesterol-lowering drugs that are extensively prescribed for primary and secondary prevention of cardiovascular disease (...) kidney-related diseases or complications. We also highlight the ongoing controversy regarding statin therapy in chronic and end-stage kidney disease. Verdoodt An A Department of Intensive Care Unit, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium. Honore Patrick M PM Department of Intensive Care Medicine, Centre Hospitalier Universitaire Brugmann, Brussels, Belgium. Jacobs Rita R Department of Intensive Care Unit, Universitair Ziekenhuis Brussel, Vrije Universiteit

Journal of translational internal medicine2018 Full Text: Link to full Text with Trip Pro

33. Use of the Kidney Failure Risk Equation to Determine the Risk of Progression to End-stage Renal Disease in Children With Chronic Kidney Disease

Use of the Kidney Failure Risk Equation to Determine the Risk of Progression to End-stage Renal Disease in Children With Chronic Kidney Disease 29255845 2018 03 16 2168-6211 172 2 2018 Feb 01 JAMA pediatrics JAMA Pediatr Use of the Kidney Failure Risk Equation to Determine the Risk of Progression to End-stage Renal Disease in Children With Chronic Kidney Disease. 174-180 10.1001/jamapediatrics.2017.4083 The kidney failure risk equation (KFRE) has been shown to accurately estimate progression (...) to kidney failure in adults with chronic kidney disease (CKD). Use of the KFRE in children with CKD, if accurate, would help to optimize planning for end-stage renal disease (ESRD) care. To determine whether the KFRE adequately discriminates the risk of ESRD in children with CKD. This retrospective cohort study included 603 children with an estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 in the Chronic Kidney Disease in Children study, a national multicenter observational study. Data

EvidenceUpdates2018

34. Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation

Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation Scotland G (...) , Cruickshank M, Jacobsen E, Cooper D, Fraser C, Shimonovich M, Marks A & Brazzelli M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Scotland G, Cruickshank M, Jacobsen E, Cooper D, Fraser C, Shimonovich M, Marks A & Brazzelli M. Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis

Health Technology Assessment (HTA) Database.2018

35. Chronic kidney disease

Chronic kidney disease Bulletin “Independent prescribing information for NHS Wales” Chronic kidney disease (CKD) is a long-term irreversible deterioration in the function of the kidneys, often in patients with diabetes and/or hypertension. It affects approximately 5.5% of adults, with a higher prevalence in older people. 1 CKD can have huge health implications for individual patients, including significantly increased risk of cardiovascular disease (CVD) and an increased vulnerability to acute (...) kidney injury (AKI). A small, but significant, number of cases progress to end-stage renal disease (ESRD) requiring dialysis or kidney transplant, which carries a major personal, social, and economic burden. Historically, CKD was considered to be a condition to be managed primarily by specialists. However, the introduction of laboratory reporting of the estimated glomerular filtration rate (eGFR) alongside serum creatinine values has improved the identification of people with CKD in primary

WeMeReC2018

36. Antihypertensive Medications and Change in Stages of Chronic Kidney Disease

Antihypertensive Medications and Change in Stages of Chronic Kidney Disease application/xhtml+xml; charset=utf-8

International journal of chronic diseases2018 Full Text: Link to full Text with Trip Pro

37. Determinant factors for chronic kidney disease after partial nephrectomy

Determinant factors for chronic kidney disease after partial nephrectomy Oncoscience 13 www.impactjournals.com/oncoscience www.impactjournals.com/oncoscience Oncoscience, Vol. 5(1-2), January 2018 Determinant factors for chronic kidney disease after partial nephrectomy Oscar D. Martín 1 , Heilen Bravo 2 , Marcos Arias 3 , Diego Dallos 5 , Yesica Quiroz 5 , Luis G. Medina 2 , Giovanni E. Cacciamani 4 and Raul G. Carlini 2 1 Clínica Cooperativa de Colombia, Universidad Cooperativa de Colombia (...) - Facultad de Medicina, Villavicencio, Colombia 2 Servicio de Nefrología y Trasplante Renal, Hospital Universitario de Caracas, Caracas, Venezuela 3 Hospital Metropolitano de Santiago (HOMS), Santiago, República Dominicana 4 Department of Urology, University of Verona, Verona, Italy 5 Fundacion Universitaria Ciencias de la Salud Hospital de San Jose, Bogotá, Colombia Correspondence to: Giovanni E. Cacciamani, email: giovanni.cacciamani@gmail.com Keywords: partial nephrectomy; chronic kidney disease

Oncoscience2018 Full Text: Link to full Text with Trip Pro

38. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.

Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a selective update of the prior CKD-MBD guideline published in 2009

Annals of Internal Medicine2018

39. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.

Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. OBJECTIVE: To assess the association between anticoagulation, ischaemic stroke, gastrointestinal and cerebral haemorrhage, and all cause mortality in older people with atrial fibrillation and chronic kidney disease. DESIGN: Propensity matched, population based, retrospective cohort analysis from (...) January 2006 through December 2016. SETTING: The Royal College of General Practitioners Research and Surveillance Centre database population of almost 2.73 million patients from 110 general practices across England and Wales. PARTICIPANTS: Patients aged 65 years and over with a new diagnosis of atrial fibrillation and estimated glomerular filtration rate (eGFR) of <50 mL/min/1.73m 2 , calculated using the chronic kidney disease epidemiology collaboration creatinine equation. Patients

BMJ2018

40. Sevelamer carbonate (Renvela) - control of hyperphosphataemia in paediatric patients with chronic kidney disease.

Sevelamer carbonate (Renvela) - control of hyperphosphataemia in paediatric patients with chronic kidney disease. Published 12 February 2018 Product Update sevelamer carbonate 2.4g powder for oral suspension (Renvela ® ) SMC No 1304/18 Sanofi 12 January 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE (...) : following an abbreviated submission sevelamer carbonate (Renvela ® ) is accepted for restricted use within NHS Scotland. Indication under review: control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m 2 ) with chronic kidney disease. SMC restriction: the second-line management of hyperphosphataemia in patients receiving haemodialysis. SMC has previously accepted sevelamer carbonate for restricted use in the second-line management of hyperphosphataemia

Scottish Medicines Consortium2018